Skip to main content
Clinical Trials/NCT06293573
NCT06293573
Active, not recruiting
Not Applicable

Comparative Effectiveness of Whole- Body Vibration and Aerobic Training Among Egyptian Elderly With Sarcopenia

Cairo University1 site in 1 country84 target enrollmentJanuary 1, 2024
ConditionsSarcopenia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sarcopenia
Sponsor
Cairo University
Enrollment
84
Locations
1
Primary Endpoint
Muscle Mass
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

To investigate and compare between the effectiveness of whole body vibration and aerobic training exercises in management of sarcopenia, muscle mass, physical performance and muscle strength in elderly.

Detailed Description

Participants will be assigned randomly into two groups of equal number (study group A and study group B ) the randomization will be performed by computerized randomization. Assessors will be blinded to the groups of the subjects. c- Subject selection 84 patients with sarcopenia will participate in this study and will be divided randomly into three equal groups with 28 participants in each group. d- Groups: Group A (Study group): Will receive whole body vibration exercises with conventional progressive resistance exercises and diet modification life style Group B (Study group): Will receive aerobic exercises training with conventional progressive resistance exercises and diet modification life style. Group C (Control Group): will receive conventional progressive resistance exercises and diet modification life style. During the study, the participants will receive study information form, instructions and signed the consent form.

Registry
clinicaltrials.gov
Start Date
January 1, 2024
End Date
December 1, 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ahmed Hussien Abdelmotaal Ali Elkadi

Assistant ecturer

Cairo University

Eligibility Criteria

Inclusion Criteria

  • patients age older than 60 years
  • patients with Skeletal muscle index (SMI) below 8.87 kg/m2 and 6.42 kg/m2 in males and females, respectively.
  • patients with hand grip strength below \< 27 kg in men and \< 16 kg in women.
  • patients with no regular exercise habit for more than 3 months .
  • patients with gait speed \> 0.8 m/s.
  • patients with proper conscious and cognition that will be detected by using Mini Mental State Examination(scores \> 21).

Exclusion Criteria

  • acute injury. 2- severe heart diseases. 3- pacemaker. 4-history of orthopedic surgery of the lower limbs and/or fracture less than 1 year earlier.
  • .5 - inability to walk without assistance. 6-neurological diseases or acute conditions that would interfere with testing and training.
  • 7-patients with improper conscious and cognition that will be detected by using Mini Mental State Examination(scores \< 21).
  • 8- patients who cannot exercise at all due to conditions like deep vein thrombosis or blood clotting issues.
  • 9- patients with severe illnesses that influence assessments and interventions, such as those with disabilities or musculoskeletal conditions (such as fracture, dislocation, osteoporosis, and rheumatoid arthritis).
  • 10- People with major spinal conditions or surgical histories, such as cauda equina syndrome, tumor, vertebral fracture, inflammatory joint disease, spondylolisthesis, and ankylosing spondylitis.
  • Every participant will get a primary checkup to get a full picture of their health, find out if there are any restrictions, and decide whether they can take part in the study.

Outcomes

Primary Outcomes

Muscle Mass

Time Frame: Muscle mass will be investigated at baseline and after the treatment period of 12 weeks.

Outcome measures included: • Skeletal muscle mass (SMM): will be measured by Bioimpedance analysis using body composition analyzer (InBody Dial H 20b).

muscle strength

Time Frame: Muscle strength will be investigated at baseline and after the treatment period of 12 weeks.

will be measured by using calibrated handheld dynamometer (CAMRY EH101).

400 m Walking Test

Time Frame: 400 m Walking Test will be investigated at baseline and after the treatment period of 12 weeks.

The 400-meters walk test evaluates a person's stamina and ability to walk. Participants in this test are required to run 20 laps of 20 meters, each lap as quickly as they can, and are permitted up to two rest breaks throughout the test.

Gait Speed test

Time Frame: Gait speed test will be investigated at baseline and after the treatment period of 12 weeks.

The 4-m usual walking speed test, which measures speed either manually ,with a stopwatch or instrumentally, with an electronic device, to measure gait timing.

timed Up and Go Test (TUG)

Time Frame: Timed Up and Go Test will be investigated at baseline and after the treatment period of 12 weeks.

The TUG test evaluates physical function, individuals will be asked to rise from a standard chair, walk to a marker 3 m away from the chair, turn around, walk back, and sit down again.

Six minute walk test (6MWT)

Time Frame: Six Minutes Walk Test will be investigated at baseline and after the treatment period of 12 weeks.

6MWT is used to measure a patient's exercise tolerance. Also it is used to assess aerobic capacity and endurance. Patient is asked to walk at his normal pace for six minutes.

Study Sites (1)

Loading locations...

Similar Trials